Clinical Trial

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy Subjects

Name: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy Subjects — clinical trial record (NCT07473752)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Completed Phase 1

View on ClinicalTrials.gov →

Summary

Trial Details

NCT Number	NCT07473752
Lead Sponsor	Tonix Pharmaceuticals, Inc. Collaborators: CTI Clinical Trial and Consulting Services
Conditions	Phase 1 First-in-human Study Involving Healthy Subjects
Enrollment	26 participants
Start Date	2023-07-18
Primary Completion	2024-02-22 (estimated)
Study Completion	2024-02-22 (estimated)
Updated on ClinicalTrials.gov	2026-03-16